Page 5 - Alexis Borisy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alexis borisy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alexis Borisy Today - Breaking & Trending Today

Ethereum Name Service (ENS) Trading 10.7% Lower Over Last 7 Days

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) fell 5.9% during mid-day trading on Thursday following insider selling activity. The company traded as low as $56.44 and last traded at $56.48. 317,027 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 581,232 shares. The stock had previously […] ....

United Kingdom , Raymond James , Brian Druker , Nicholasb Lydon , Percyh Carter , Chris Varma , Capital Impact Advisors , Needham Company , Blueprint Medicines Corp , Macquarie Group Ltd , Jpmorgan Chase Co , Blueprint Medicines Co , Squarepoint Ops , Blueprint Medicines Company Profile , Blueprint Medicines , Get Rating , Impact Advisors , Bay Capital Management , Alexis Borisy , Blueprint Medicines Daily ,

Blueprint Medicines (NASDAQ:BPMC) vs. Hypera (OTCMKTS:HYPMY) Critical Survey

Blueprint Medicines (NASDAQ:BPMC – Get Rating) and Hypera (OTCMKTS:HYPMY – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Analyst Recommendations This is a summary of current recommendations and price […] ....

United Kingdom , Brian Druker , Celestone Soluspan , Chris Varma , Dermotil Fusid , Nicholasb Lydon , Mal Dexchlorpheniramine , Blueprint Medicines Corp , Blueprint Medicines , Get Rating , Given Blueprint Medicine , Alexis Borisy , Derivec Micro , Micro Drift , Peridal Suspension , Mantecorp Skincare , Sodium Diclofenac , Losartan Potassium , Blueprint Medicines Daily , Nasdaq Bpmc , Stock Comparison , Stock Analysis ,

Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 5.8% in May

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 3,580,000 shares, a decline of 5.8% from the April 30th total of 3,800,000 shares. Based on an average trading volume of 598,200 shares, the […] ....

United Kingdom , Christopherk Murray , Jeffreyw Albers , Chris Varma , Brian Druker , Nicholasb Lydon , Lazard Asset Management , Associates Corp , Bessemer Group Inc , Blueprint Medicines Corp , Needham Company , Proficio Capital Partners , Blueprint Medicines Co , Securities Exchange Commission , Blueprint Medicines , Get Rating , Exchange Commission , Director Jeffrey , Capital Partners , Asset Management , Dark Forest Capital Management , Medicines Stock Down , Alexis Borisy , Blueprint Medicines Daily , Nasdaq Bpmc ,

Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $46.00

Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price target lifted by Barclays from $44.00 to $46.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other analysts have also issued reports on the company. Stifel Nicolaus boosted their price objective on Blueprint Medicines from $80.00 to $84.00 in […] ....

United Kingdom , Brian Druker , Nicholasb Lydon , Stifel Nicolaus , Chris Varma , Christina Rossi , Christopherk Murray , Macquarie Group Ltd , Emerald Advisers , Needham Company , Connor Clark Lunn Investment Management Ltd , Putnam Investments , Morgan Stanley , Blueprint Medicines Corp , Blueprint Medicines , Get Rating , Moderate Buy , Lunn Investment Management , Alexis Borisy , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Barclays Plc ,

Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $82.00 by Analysts at Guggenheim

Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its target price boosted by Guggenheim from $78.00 to $82.00 in a report published on Tuesday, The Fly reports. A number of other equities analysts have also recently weighed in on the stock. JMP Securities reaffirmed a market outperform rating and set a $114.00 price target on shares […] ....

United Kingdom , Raymond James , Jeffreyw Albers , Chris Varma , Stifel Nicolaus , Brian Druker , Nicholasb Lydon , Kate Haviland , Proficio Capital Partners , Blueprint Medicines Corp , Bessemer Group Inc , Securities Exchange Commission , Lazard Asset Management , Associates Corp , Blueprint Medicines Company Profile , Blueprint Medicines , Get Rating , Moderate Buy , Director Jeffrey , Exchange Commission , Capital Partners , Asset Management , Dark Forest Capital Management , Alexis Borisy , Blueprint Medicines Daily , Nasdaq Bpmc ,